JCAD Expression and Clinical Outcomes in Hepatocellular Carcinoma

102 pairs of human HCC and adjacent normal tissues were analyzed via immunohistochemistry for JCAD protein expression. The dataset, authored by Zhonghua Wang and last updated in May 2026, integrates bioinformatics analysis from TCGA, GEO, and GTEx with clinical validation. Elevated JCAD expression was significantly associated with portal vein tumor thrombosis and reduced disease-free survival.

Use Cases

• Assessing the prognostic value of JCAD expression based on its correlation with overall survival and disease-free survival.
• Investigating associations between gene expression and clinicopathological features like tumor stage and differentiation grade.
• Analyzing the correlation between JCAD expression and immune cell infiltration levels in the tumor microenvironment.
• Validating bioinformatics findings from public databases with primary clinical tissue samples.

Strengths

• Clinical validation includes 102 pairs of HCC and adjacent normal tissue samples.
• Analysis integrates data from multiple authoritative sources including TCGA, GEO, and GTEx.
• Provides specific statistical results, such as an AUC of 0.695 for predicting DFS.

Limitations

• The specific column names and row count of the underlying data are unknown.
• The dataset is stored as a 1.2 MB DOCX file, which may require extraction of structured data.
• Description metadata is limited; actual data quality requires manual inspection after download.

Provenance

Source

The Cancer Genome Atlas (TCGA), Gene Expression Omnibus (GEO), Genotype-Tissue Expression (GTEx), and primary clinical samples.

Collection Method

Bioinformatics analysis combined with immunohistochemistry on clinical tissues.

Freshness

Last updated 2026-05-28 06:20:03